{"filing":{"accession_number":"0001193125-26-306688","cik":"0001778016","ticker":"NBP","company_name":"NovaBridge Biosciences","form":"6-K","filing_date":"2026-07-17","report_date":null,"primary_document":"6-k_-_2026_esop.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1778016/000119312526306688/6-k_-_2026_esop.htm"},"events":[{"id":18548,"run_id":16674,"accession_number":"0001193125-26-306688","anchor_item_number":"EX-99.1","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"This exhibit is the 2026 Omnibus Share Incentive Plan adopted by the Board on July 13, 2026. It establishes a comprehensive equity compensation framework authorizing grants of options, restricted shares, share units, and cash-based awards to employees, consultants, and directors. The plan document itself—setting forth the terms, conditions, and administration of compensatory arrangements—constitutes a material disclosure of executive and employee compensation arrangements under Item 5.02(e) equivalent disclosure obligations for foreign private issuers.","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-07-17","form":"6-K","submitted_at":null,"items":[{"id":17390,"accession_number":"0001193125-26-306688","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This exhibit is the 2026 Omnibus Share Incentive Plan adopted by the Board on July 13, 2026. It establishes a comprehensive equity compensation framework authorizing grants of options, restricted shares, share units, and cash-based awards to employees, consultants, and directors. The plan document itself—setting forth the terms, conditions, and administration of compensatory arrangements—constitutes a material disclosure of executive and employee compensation arrangements under Item 5.02(e) equivalent disclosure obligations for foreign private issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-17T10:06:43.992381+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17390,"accession_number":"0001193125-26-306688","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This exhibit is the 2026 Omnibus Share Incentive Plan adopted by the Board on July 13, 2026. It establishes a comprehensive equity compensation framework authorizing grants of options, restricted shares, share units, and cash-based awards to employees, consultants, and directors. The plan document itself—setting forth the terms, conditions, and administration of compensatory arrangements—constitutes a material disclosure of executive and employee compensation arrangements under Item 5.02(e) equivalent disclosure obligations for foreign private issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-17T10:06:43.992381+00:00","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-07-17"}]}